Patents by Inventor Jillian M. Prendergast
Jillian M. Prendergast has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240343834Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.Type: ApplicationFiled: November 13, 2023Publication date: October 17, 2024Applicants: Seagen Inc., The General Hospital CorporationInventors: David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
-
Publication number: 20240000962Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.Type: ApplicationFiled: November 7, 2022Publication date: January 4, 2024Applicant: Seagen Inc.Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
-
Publication number: 20240002422Abstract: The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.Type: ApplicationFiled: February 28, 2023Publication date: January 4, 2024Applicant: Seagen Inc.Inventors: Ana Paula Galvao da Silva, Mai Zhang, Darius Ghaderi, Julie DeSander, Jeffrey Behrens, Jillian M. Prendergast
-
Publication number: 20240002537Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.Type: ApplicationFiled: November 7, 2022Publication date: January 4, 2024Applicants: Seagen Inc., The General Hospital CorporationInventors: David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
-
Publication number: 20230331868Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.Type: ApplicationFiled: June 14, 2023Publication date: October 19, 2023Applicant: Seagen Inc.Inventors: David A. Eavarone, Jillian M. Prendergast, Jeffrey Behrens
-
Publication number: 20230312747Abstract: Methods of detecting, characterizing, and targeting myeloid-derived suppressor cells are disclosed. Some methods include the use of glycan-interacting antibodies, such as anti-STn antibodies. Methods of identifying subjects for treatment with glycan-interacting antibodies are included.Type: ApplicationFiled: December 6, 2022Publication date: October 5, 2023Applicant: Seagen Inc.Inventors: Jillian M. Prendergast, David A. Eavarone, Patricia Rao
-
Publication number: 20230029085Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.Type: ApplicationFiled: March 16, 2022Publication date: January 26, 2023Applicants: Seagen Inc., The General Hospital CorporationInventors: David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
-
Publication number: 20230001007Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.Type: ApplicationFiled: January 4, 2022Publication date: January 5, 2023Applicant: Seagen Inc.Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
-
Publication number: 20220259323Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.Type: ApplicationFiled: December 1, 2021Publication date: August 18, 2022Applicant: Seagen Inc.Inventors: David A. Eavarone, Jillian M. Prendergast, Jeffrey Behrens
-
Publication number: 20220057402Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.Type: ApplicationFiled: May 26, 2021Publication date: February 24, 2022Applicant: Seagen Inc.Inventors: Ana Paula Galvao da Silva, Darius Ghaderi, Mai Zhang, Kristan Meetze, Julie DeSander, Jeffrey Behrens, David A. Eavarone, Jillian M. Prendergast
-
Patent number: 11253609Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.Type: GrantFiled: March 2, 2018Date of Patent: February 22, 2022Assignee: Seagen Inc.Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
-
Patent number: 11028181Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.Type: GrantFiled: November 10, 2016Date of Patent: June 8, 2021Assignee: Seagen Inc.Inventors: David A. Eavarone, Jillian M. Prendergast, Jeffrey Behrens
-
Publication number: 20210017213Abstract: The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.Type: ApplicationFiled: April 16, 2020Publication date: January 21, 2021Applicant: Seattle Genetics, Inc.Inventors: Ana Paula Galvao da Silva, Mai Zhang, Darius Ghaderi, Julie DeSander, Jeffrey Behrens, Jillian M. Prendergast
-
Publication number: 20210011021Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.Type: ApplicationFiled: February 14, 2020Publication date: January 14, 2021Applicant: Seattle Genetics, Inc.Inventors: Ana Paula Galvao da Silva, Darius Ghaderi, Mai Zhang, Kristan Meetze, Julie DeSander, Jeffrey Behrens, David A. Eavarone, Jillian M. Prendergast
-
Publication number: 20200247902Abstract: Methods of detecting, characterizing, and targeting myeloid-derived suppressor cells are disclosed. Some methods include the use of glycan-interacting antibodies, such as anti-STn antibodies. Methods of identifying subjects for treatment with glycan-interacting antibodies are included.Type: ApplicationFiled: November 17, 2017Publication date: August 6, 2020Applicant: Seattle Genetics, Inc.Inventors: Jillian M. Prendergast, David A. Eavarone, Patricia Rao
-
Publication number: 20200000932Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.Type: ApplicationFiled: March 2, 2018Publication date: January 2, 2020Applicant: SEATTLE GENETICS, INC.Inventors: Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
-
Publication number: 20190031780Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.Type: ApplicationFiled: January 27, 2017Publication date: January 31, 2019Inventors: David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
-
Publication number: 20180327509Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.Type: ApplicationFiled: November 10, 2016Publication date: November 15, 2018Inventors: David A. Eavarone, Jillian M. Prendergast, Jeffrey Behrens, Alexey Alexandrovich Lugovskoy, Daniel T. Dransfield
-
Publication number: 20170306046Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. Further provided are methods of using glycan-interacting antibodies to target cells and treat disease.Type: ApplicationFiled: November 12, 2015Publication date: October 26, 2017Inventors: Ana Paula Galvao daSilva, Darius Ghaderi, Mai Zhang, Kristan Meetze, Julie DeSander, Jeffrey Behrens, David A. Eavarone, Jillian M. Prendergast, Alexey Alexandrovich Lugovskoy
-
Publication number: 20170305950Abstract: The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.Type: ApplicationFiled: October 9, 2015Publication date: October 26, 2017Inventors: Ana Paula Galvao da Silva, Mai Zhang, Darius Ghaderi, Julie DeSander, Jeffrey Behrens, Jillian M. Prendergast
